Vanguard Group Inc. Sells 146,536 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Vanguard Group Inc. decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 1.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 14,169,665 shares of the medical research company’s stock after selling 146,536 shares during the quarter. Vanguard Group Inc. owned 11.10% of NeoGenomics worth $229,265,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Brown Advisory Inc. boosted its position in shares of NeoGenomics by 16.9% during the 4th quarter. Brown Advisory Inc. now owns 9,643,599 shares of the medical research company’s stock valued at $156,033,000 after acquiring an additional 1,397,397 shares in the last quarter. First Light Asset Management LLC boosted its holdings in NeoGenomics by 29.6% during the fourth quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company’s stock valued at $63,535,000 after purchasing an additional 897,843 shares in the last quarter. Norges Bank bought a new stake in shares of NeoGenomics in the 4th quarter valued at approximately $14,512,000. Schroder Investment Management Group raised its holdings in shares of NeoGenomics by 26.7% in the 3rd quarter. Schroder Investment Management Group now owns 2,513,307 shares of the medical research company’s stock worth $30,914,000 after buying an additional 529,178 shares in the last quarter. Finally, Lisanti Capital Growth LLC bought a new position in shares of NeoGenomics during the 4th quarter worth approximately $3,445,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on NEO. BTIG Research lowered their price target on NeoGenomics from $23.00 to $21.00 and set a “buy” rating on the stock in a research report on Thursday, May 2nd. Craig Hallum assumed coverage on shares of NeoGenomics in a report on Wednesday, May 1st. They issued a “buy” rating and a $26.00 target price on the stock. Benchmark reissued a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a report on Wednesday, May 1st. TD Cowen decreased their price objective on shares of NeoGenomics from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Finally, Needham & Company LLC dropped their price objective on shares of NeoGenomics from $24.00 to $19.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $19.78.

NeoGenomics Price Performance

Shares of NEO stock opened at $13.93 on Tuesday. NeoGenomics, Inc. has a 1 year low of $11.03 and a 1 year high of $21.22. The company has a current ratio of 7.48, a quick ratio of 7.22 and a debt-to-equity ratio of 0.58. The firm’s 50 day moving average is $14.09 and its 200-day moving average is $15.15. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -21.11 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $156.24 million for the quarter, compared to analyst estimates of $149.82 million. NeoGenomics had a negative return on equity of 3.54% and a negative net margin of 13.79%. Sell-side analysts forecast that NeoGenomics, Inc. will post -0.21 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.